Skip to content

CES 2023:OMRON Healthcare Introducing Initiatives to Advance Its Vision of “Going for Zero” — Elimination of Heart Attack and Stroke

By asianet

OMRON Healthcare Co., Ltd. (hereinafter the Company) will exhibit at CES 2023 (*), the world’s largest consumer tech show taking place in Las Vegas from Thursday, January 5, through Sunday, January 8. At the show, the Company will showcase the innovative medical devices and digital services that have been introduced over the last 50 years … Continued

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

By asianet

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock. In … Continued

Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

By asianet

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the “notes”). The notes are being offered and sold only to persons reasonably believed to be … Continued

Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes

By asianet

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the “notes”). The notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant … Continued

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

By asianet

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Phase II/III randomized, controlled trial Pharming Group N.V. (“Pharming” or “the … Continued

Hovione and GEA announce a strategic collaboration to advance Continuous Tableting

By asianet

Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s development and manufacturing experience and both parties commit to partner to accelerate the adoption of Continuous Tableting technology. The advantages of continuous over batch manufacturing … Continued

Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH(R) System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease

By asianet

Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH(R) System and the CELLSERCH(R) Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages /PRNewswire/ — Menarini Silicon Biosystems, a pioneer of liquid biopsy and single … Continued

Lost childhood: a ‘tight-knit’ network to combat abuse and distress

By asianet

On Radar takes off, the first meeting of the Think Tank of Fondazione Internazionale Menarini Setting real changes in motion through dialogue among experts in order to tackle the unresolved issues of juvenile distress. This was the topic addressed during the first meeting of the ‘On Radar’ Think Tank of Fondazione Internazionale Menarini held in … Continued

Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH’s Blood

By asianet

Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients’ immune dysregulation and deficiency The peer-reviewed publication heightens international understanding of APDS, a rare and recently characterized immunodeficiency Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that the … Continued